CliffBio
small molecule

TASCENSO ODT

FINGOLIMOD LAURYL SULFATE

Loss of exclusivityJanuary 2036latest FDA-listed patent expiry
CompanyCycle Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameTASCENSO ODT
Active ingredientFINGOLIMOD LAURYL SULFATE
StrengthEQ 0.25MG BASE
Dosage formTABLET, ORALLY DISINTEGRATING
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2021
Marketing statusRX

Listed patents

PatentExpiresType
10555902January 2036use U-3268
9925138January 2036product
10925829January 2036product

More from Cycle Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TASCENSO ODT patent cliff — loss of exclusivity January 2036 | CliffBio